ArticleInflammation2025
ACE2 Alleviates Microglia Neuroinflammation by RANK-RANKL-OPG Axis in Parkinson's Disease.
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α-synuclein preformed fibrils-induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines.Brain pathology (Zurich, Switzerland) · 2026Article
- RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma.Investigative ophthalmology & visual science · 2026Observational
- Microglial activation and RAS signaling: a dual-edged sword in neuroinflammation.American journal of physiology. Regulatory, integrative and comparative physiology · 2026Review
- Microglia heterogeneity and therapeutic strategies in Parkinson's disease.Frontiers in immunology · 2026Review
- Ferroptosis in Parkinson's disease: a review of molecular mechanisms and emerging therapeutic strategies.Frontiers in neuroscience · 2026Review
- Review
- Brain-Bone Axis in Physiological and Pathological Conditions.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Parkinson's disease (PD) and osteoporosis are prevalent age-related conditions. Notably, individuals with PD exhibit a markedly elevated risk of osteoporosis and fractures. Osteoprotegerin (OPG), a critical regulator of bone homeostasis, may also influence neuroinflammatory processes. Microglial overactivation, which triggers neuroinflammation, is a key pathogenic mechanism in PD, making the regulation of microglial activity a promising therapeutic approach. Recent studies suggest that Angiotensin-Converting Enzyme-2 (ACE2) is involved in OPG expression and can modulate immune responses. However, the role of OPG in PD progression and whether ACE2 influences microglial function via OPG remain poorly understood. To investigate this interaction, we employed ACE2 knock-in (hACE2) mice and ACE2-transfected BV2 microglial cells. Our findings demonstrate that ACE2 modulation alters the non-classical NF-κB activation pathway by regulating the RANK-RANKL-OPG axis in microglia. This regulation mitigates neuroinflammatory responses and reduces dopaminergic neuronal loss. These results provide insights into the role of the RANK-RANKL-OPG axis in PD and elucidate mechanisms through which ACE2 regulates neuroinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.